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EgyptAbstract Background: Variceal hemorrhage (VH) is a major complication of chronic liver disease.
Several factors have been validated for the prediction of the outcome of an acute VH. The clinical
risk characteristics reported in developed countries may be different from developing countries.
Aim: The aim of this study was to determine the predictors of mortality in patients admitted to our
hospital with acute upper gastrointestinal (UGI) hemorrhage who underwent endoscopy and con-
ﬁrmed to have VH.
Patients and methods: This was a cross sectional hospital based study performed over a seven-year
period between January 2006 and January 2013.
Results: A total of 224 patients were analyzed. Nineteen patients (8%) died within the ﬁrst two
weeks of their hospital admission. Eighteen variables were studied and included in a multivariate
analysis using a logistic regression model. Five variables were predictors of death. Hemodynamic
instability at admission (AOR= 5.5, 95% CI = 22.3 + 1.4, P= 0.017), Child class C
(AOR= 5.9, 95% CI = 24 + 1.5, P= 0.013), blood in upper gastrointestinal (UGI) tract at the
296 A. Gado et al.index endoscopy (AOR= 12.8, 95% CI = 126.5 + 1.3, P= 0.03), rebleeding within ﬁve days of
endoscopy (AOR= 25.4, 95% CI = 109.2 + 5.9, P= 0.000), and in-hospital complications
(AOR= 23.4, 95% CI = 122.5 + 4.5, P= 0.000) were independent predictors of mortality after
the acute VH episode.
Conclusion: Patients with acute VH and hemodynamic instability at admission, Child class C,
blood in UGI tract at the index endoscopy, rebleeding within ﬁve days of endoscopy and in-hospital
complications are at an increased risk of mortality after the acute VH episode. Rebleeding within
ﬁve days of endoscopy and in-hospital complications are the most signiﬁcant independent predic-
tors of mortality.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Variceal hemorrhage (VH) is a major complication of chronic
liver disease and is associated with signiﬁcant morbidity and
mortality.1,2 Although overall survival may be improving over
the past 40 years, mortality is still closely related to failure to
control bleeding or early rebleeding and this is not uncommon
during the ﬁrst days to 6 weeks after admission.2–5
A variety of clinical risk characteristics have been adopted
to assist with patient assessment and a number of them have
been applied for use in prognostic scoring algorithms (e.g.
Rockall score). These are used to evaluate risk of death and/
or re-bleeding in upper gastrointestinal (UGI) hemorrhage
patients, and also to screen for and to select high risk patients
for intervention within an appropriate time. Several factors
have been speciﬁcally validated for the prediction of the out-
come of acute VH.5,6
Prognostic factors of mortality in acute VH included pre-
sentation with hematemesis, failure to control bleeding within
ﬁve days, raised bilirubin, presence of ascites, encephalopathy,
shorter interval to admission to hospital, plasma urea, bleeding
starting in hospital, prothrombin time <40%, recent use of
steroid drugs within seven days of bleeding, age > 60 years,
hepatic venous pressure gradient, concomitant hepatocellular
cancer and transfusion need.6
The clinical risk characteristics reported in developed coun-
tries may be different from those in developing countries.
Egypt has a large burden of chronic liver disease. Schistoso-
miasis and hepatitis C virus are common diseases in Egypt. The
overall prevalence positive for antibody to hepatitis C virus was
14.7%.7 Despite the advent of endoscopy and endoscopic ther-
apy, access tomedical centerswith experiencedmedical staff and
adequate equipment in Egypt is still limited. Most government
hospitals refer patients with acute UGI hemorrhage to teaching
hospitals, academic institutes, insurance hospitals and
private hospitals. Many patients never reach hospital. A plan
for management of UGI hemorrhage was designed in a govern-
mental hospital to be within the available resources and was
formulated in two stages. Stage one, 2000–2004, was the training
of staff and preparation. During this time we assessed the
capability of the hospital for dealing with these cases. Following
the assessment we went to stage two. Stage two started in 2004
and all patients presenting with acute UGI hemorrhage have
been assessed and managed in house.8–10
The aim of this study was to determine the predictors of
mortality in patients admitted to our hospital with acuteUGI hemorrhage who underwent endoscopy and conﬁrmed
to have VH.
2. Patients and methods
This was a cross sectional hospital based study. The study was
performed in a secondary-care governmental hospital (Bolak
Eldakror Hospital, Giza, Egypt) on cirrhotic patients present-
ing with acute UGI hemorrhage who underwent endoscopy
and conﬁrmed to have VH over a seven-year period between
January 2006 and January 2013.
A management plan for acute UGI hemorrhage composed
of ﬁve steps (assessment, resuscitation, diagnosis, stoppage of
bleeding and prevention of rebleeding) was designed. A man-
agement protocol, based on international standards, was
established with the intention of improving the quality and
efﬁciency of our health care delivery (Table 1).11,12 Clinical
guidelines and a clinical care pathway were developed within
the availability of local therapeutic options in order to provide
a stand-alone practical guide for the team (Table 1). The care
pathway was developed to improve patient management and
resource utilization. The guidelines and care pathway were dis-
seminated to house ofﬁcers, residents, physicians, and nursing
staff. This was accomplished via medical rounds and confer-
ences for the medical staff. Printed sheets were posted in the
emergency room, intensive care and medical department that
outlined the care pathway. A consultant gastroenterologist
was on-call 24/7 days a week to attend resuscitation when
bleeding was detected. The gastroenterologist served as a
facilitator for the medical staff caring for the patients, often
monitoring intravenous hydration and delivering blood/blood
products.
Stratiﬁcation of patients in low and high-risk categories for
rebleeding and mortality was performed using the Rockall
score. Patients with a low risk were discharged home and
subsequently underwent diagnostic endoscopy on the next
available list. Those at high risk were admitted to hospital
for intensive monitoring and early, energetic resuscitation.
Endoscopy was performed on the morning of the second day
to establish diagnosis, to control bleeding and to prevent reb-
leeding if considered appropriate. All patients presenting with
acute UGI hemorrhage and a conﬁrmed diagnosis of liver cir-
rhosis were admitted, assessed and resuscitated in a three-bed
intensive-care unit. Liver cirrhosis was diagnosed on the basis
of clinical and laboratory data and ultrasonography. Child
classiﬁcation was used to assess hepato-cellular function in
Table 1 Upper gastrointestinal hemorrhage care pathway.
Deﬁnition
Acute UGI hemorrhage is bleeding started within 3–7 days from presentation
Admission day
 Admit any patient with bleeding or suspicious of bleeding
 History, physical examination and initial hemoglobin level
 Hemodynamic stability: normal pulse and blood pressure in both supine and erect position
 Hemodynamic instability: heart rate > 100 beats/min, hypotension with a systolic pressure < 90 mmHg and/or diastolic
value < 60 mmHg
Initial management
 If young, hemodynamically stable, has minor co morbidity (hypertension or diabetes mellitus) and does not have major co morbidity: dis-
charge the patient home and endoscopy can be done as outpatient (elective/scheduled)
 If elderly (>60 years), hemodynamically instable or with major co morbidity: admit the patient in the intensive care unit of UGI bleeding
 Inform the on call specialist to attend and monitor until the patient is stable (systolic blood pressure > 100 mmHg in 2 readings 10 min
apart)
 Secure airways
 IV access with 2 peripheral cannulae (16 gauge)
 Cross match for at least 2 units of blood
 Insert a nasogastric tube and perform aspirate and lavage procedure. Do not insert the tube if the patient could not tolerate it
 Rectal examination to assess stool color
 Insert urinary catheter and measure hourly volume
 1–2 L of saline will correct volume losses. If the patient remains unstable add plasma expanders (hemagel) and blood
 Blood transfusion is continued until the patients is stable and hemoglobin level reaches 7–8 g/dl in patients with liver cirrhosis, 9–10 g/dl in
patients without liver cirrhosis, 11–12 g/dl in patients with ischemic heart disease
 If blood is not available contact other governmental blood banks through Giza Governorate of Health direct line or National Blood Bank
in Dokki. Both are in service 24/7
 IM vitamin K every 12 h if the patient has bleeding tendency
 Prophylactic antibiotic therapy (IV third generation cephalosporin or oral ciproﬂoxacin 1 g/d for I week) if the patient has liver cirrhosis
 Lactulose orally and enema once daily in case of encephalopathy
 Analgesic or anxiolytic if the patient has severe pain or irritable (IV pethidine 25 mg or diazepam 5 mg, Half the dose should be used in
elderly and those with cardio respiratory disease)
 Insulin if the patient has diabetes mellitus
 ECG if the patient has cardiac co morbidity or in shock at presentation
 Plain X-ray chest if the patient has rales, wheeze, bronchial breathing
 Plain X-ray abdomen if the patient has peritoneal signs, severe tenderness, vomiting with distention
 Vasoactive drugs (e.g. IV sandostatin or glypressin) can be used, when available in the future, in case of suspicious of variceal bleeding
 IV proton pump inhibitors can be used, when available in the future, in case of suspicious of peptic ulcer bleeding
Monitoring
 Vital signs every one hour until stable then every 4–8 h until time of endoscopy
 Hemoglobin or hematocrit every 6–12 h
 If bleeding stops and the patient is stable, transfer to the general medical ward and allow ﬂuid to drink
 If bleeding continues the patient should be kept in the intensive care fasting with IV ﬂuid replacement
Morning of the next day
 Blood sample for all routine laboratory tests
 Ultrasonography of abdomen
 Endoscopy is undertaken in the morning of the next day. The patient should be alert and hemodynamically stable
Procedure
 Patients who have either endoscopically diagnosed bleeding varices or peptic ulcer with a visible vessel or active bleeding should receive
endoscopic therapy in a variety of forms at the time of initial endoscopy according to the protocol
Post procedure
 If bleeding is controlled transfer the patient to the general medical ward
 Allow the patient to eat or drink after 6 h from therapeutic endoscopy
 If therapeutic endoscopy was performed for variceal hemorrhage: oral proton pump inhibitors for 2 weeks and paracetamol (for chest pain)
 If therapeutic endoscopy was performed for ulcer hemorrhage: IV proton pump inhibitors for 48 h then continue with ordinary dose
 If ulcer hemorrhage without therapeutic endoscopy: start treatment with oral H2 antagonist or proton pump inhibitors
 If bleeding is not controlled or rebleeding occurs transfer the patient to the intensive care, assess, start resuscitation and repeat endoscopy is
arranged
Follow up
 Vital signs is measured every 8 h and hemoglobin every 12–24 h for the following 48 h
 Patients should be observed for ﬁve days
Discharge criteria
 No evidence of on-going bleeding
 No orthostatic signs at discharge
(continued on next page)
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Table 1 (continued)
Patient discharge
Discharge information includes:
 Medical follow up in the outpatient clinic within 2 weeks
 An appointment for the second therapeutic session in cases of variceal hemorrhage
Management of variceal hemorrhage
Endoscopic diagnosis of variceal hemorrhage
 Active bleeding from a varix
 Clots overlying a varix
 A white nipple a rupture point on a varix
 Varices in absence of another potential source of bleeding
Esophageal varices (EV) grading
 Grade 1: varices that collapse to inﬂation of the esophagus with air
 Grade 2: varices between grades 1 and 3
 Grade 3: varices which are large enough to occlude the lumen
Gastric varices (GV) classiﬁcation
 Primary: GV that can be detected at the ﬁrst endoscopy
 Secondary: GV that occur within two years of eradication of EV
Types of gastric varices
 Gastro-esophageal varices (GEV) types 1 and 2: those GV that are continuous with EV and occur along the lesser curvature or the fundus,
respectively
 Isolated gastric varices types 1 and 2 (IGV): those GV that are discontinuous from the EV and occur either in the fundus of the stomach or
anywhere else in the stomach, including the body, antrum, pylorus, and duodenum, respectively. GV can occur in the absence of EV or in
the presence of only grade I EV
Control of acute variceal hemorrhage
– Esophageal varices
 Band ligation is the method of ﬁrst choice
 If banding is difﬁcult because of continued bleeding sclerotherapy should be performed
 Injection sclerotherapy with ethanolamine oleate is ﬁrst choice and if failure to control bleeding histoacryl can be used
– Gastric varices
 Baveno IV consensus: Treat all GV with histoacryl
 BSG guidelines 2000: Treat GEV as for EV and IGV with histoacryl
Secondary prophylaxis of variceal hemorrhage
– Non-selective beta blockers with or without endoscopic therapy
– Esophageal varices
 Band ligation after 4–10 days, then every 2–4 weeks until eradication then every 3–6 months. Single band to each varix
 Sclerotherapy to other small vessels and to complete eradication
– Gastric varices
 A repeat session for GEV should be done after one week (unless there is diffuse ulcers) and on weekly basis. IGV usually requires one or
two sessions for obliteration
Injection of sclerosant
– Injection sclerotherapy of EV using ethanolamine oleate
 Use 23- gauge sclerotherapy needle
 Intravariceal or perivariceal injection
 2–4 ml is injected into a single EV
 During active bleeding start injection below the site of bleeding
 During follow up start injection at Z line
– Injection sclerotherapy of GV using histoacryl
 All attendants should use goggles during the procedure
 Use 21-gauge sclerotherapy needle with 6–8 mm long needle tip
 Prepare a mixture of 0.5 ml of histoacryl with 0.7 ml of lipiodol
 Use 5 ml syringe and inject 1.2–4.6 ml in of this mixture into single GV
 All GV must be injected at the same time and should be Intravariceal
 For better view of the fundus especially with IGV1 or GOV2: the patient in the prone or right lateral position, head end of the patient
raised to 30–45 degree and injection is performed by retroﬂexion the endoscope
 To avoid injury of endoscope channel: before retroﬂexion push the injector outside the tip for 1 cm
 To ﬁx the tip of the endoscope in front of fundal varices: after retroﬂexion of the endoscope, lock the right-left knob
 Precautions for preventing endoscope channel and injector blockage: apply lipiodol at the tip of the endoscopic channel, avoid suction
during injection of the glue, water irrigation after injection of the glue and do not pull the injector out through the endoscopic channel
until the injector is properly cleaned from any adherent material
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Table 1 (continued)
Management of peptic ulcer hemorrhage
Stigmata of recent hemorrhage
 Clean base
 Red or dark blue ‘‘ﬂat spot’’
 Adherent clot
 Non-bleeding visible vessel
 Active bleeding
Indications for endoscopic therapy in ulcer hemorrhage
 Ulcer with clean base: no endoscopic therapy
 Ulcer with red or dark blue ‘‘ﬂat spot’’: no endoscopic therapy
 Ulcer with adherent clot: Vigorous water irrigation to dislodge the clot and endoscopic therapy if visible vessel or active bleeding
 Ulcer with non-bleeding visible vessel: Endoscopic therapy
 Ulcer with active bleeding: Endoscopic therapy
Endoscopic therapy for peptic ulcer hemorrhage
 Epinephrine injection and thermal electrocoagulation
 Epinephrine is diluted (1:10,000) and administered through a 23-gauge sclerotherapy needle. 2 ml can be given in increments targeting four
quadrants of the ulcer. Larger volumes (35–45 ml) were more effective in providing hemostasis as compared to standard volumes (15–25 ml)
though there are no clear guidelines as to the ideal volume required
 Thermal (bipolar) electrocoagulation: The probe, of Boston Scientiﬁc Corp., is forcefully opposed directly on the major stigmata of hem-
orrhage and pulse treatment of 5–10 s with a power of 10–15 W are applied followed by water irrigation until target coagulation is achieved
Follow up after endoscopic therapy
 IV proton pump inhibitors for 48 h then continue with ordinary dose
 Hemostasis after ﬁrst endoscpoic therapy is usually achieved in more than 94% of procedures when thermocoagulation of bleeding lesions is
used
 After bleeding from ulcers is controlled endoscopically the rate of recurrent bleeding is 15 to 20%
 The minority of patients in whom hemostasis is not achieved by an initial endoscopic therapy or rebleeding occurs at least one more endo-
scopic therapy is preferable to surgery
Indications of surgery
 Failure of endoscopic therapy: common in posterior wall duodenal ulcers or large ulcer
 Active severe bleeding during endoscopy
Types of surgery
– According to patient’s condition, competence and preference of the surgeon
– Conservative surgery (minimal surgery)
 Underrunning of the bleeding vessel or ulcer excision
 Followed by H2 antagonist
– Conventional surgery (ulcer-curing surgery)
 Vagotomy and gastrectomy or vagotomy and pyloroplasty
Predictors of mortality after acute variceal hemorrhage 299cirrhosis. Every patient was assigned a class based on the pres-
ence of ascites, neurological disorder, nutritional status, serum
bilirubin and albumin levels. Histological examination of the
liver was not performed. The etiology of the liver disease
was not determined in any patient. Those who were hemody-
namically unstable (heart rate > 100 beats/minute, hypoten-
sion with a systolic pressure < 90 mmHg and/or diastolic
value < 60 mmHg) were managed with crystalloid solutions
with or without blood transfusion. Patients with hemoglobin
less than 7 g/dl were transfused according to individual
requirements. All patients suspected to have VH received pro-
phylactic antibiotic therapy (IV third generation cephalospo-
rin). Endoscopy was performed on the morning of the
second day to establish the diagnosis, to control bleeding
and prevent rebleeding. All patients received conscious seda-
tion. IV midazolam (2.5 mg) was the agent used. All endoscop-
ies were performed by two well-trained experienced
endoscopists. All patients with VH received initial endoscopic
therapy (sclerotherapy, band ligation or both). If hemostatic
therapy was unsuccessful, either because bleeding was not
controlled or rebleeding occurred, repeat endoscopy wasconsidered. Balloon tamponade, vasoactive drugs, surgical
shunts and trans-jugular intrahepatic porto-systemic shunts
were not locally available. Patients were observed in the med-
ical department for a minimum of ﬁve days before discharge.
During the study period 500 patients with concomitant
acute UGI hemorrhage and liver cirrhosis were admitted.
One hundred and forty-two patients (28%) did not undergo
an inpatient endoscopy for various reasons and 358 patients
(72%) underwent endoscopy (Tables 2 and 3). Patients who
did not undergo inpatient endoscopy and those who had non
variceal hemorrhage were excluded.
Two hundred and twenty-four patients with concomitant
acute UGI hemorrhage and liver cirrhosis who underwent
endoscopy and conﬁrmed to have VH were included in the
analysis. A standardized data collection form (sheet) was com-
pleted for each patient. Recorded data included demographic
information and historical data: smoking history, drugs used
(aspirin, non-steroidal anti-inﬂammatory drugs and anticoagu-
lants), alcohol consumption, patient condition at the time of
bleeding, presenting symptoms and co-morbid illnesses.
Physical and laboratory examination ﬁndings included
Table 2 Patients with liver cirrhosis and acute UGI hemor-
rhage who did not undergo endoscopy.
Causes Incidence (%)
Died rapidly on admission 45 (9%)
Unﬁt for endoscopy 35 (7%)
Speciﬁcally categorized as terminal care
patients
32 (6.4%)
Self-discharging prior to endoscopy being
undertaken
9 (1.8%)
Refused or whose family refused to consent to
endoscopy
7 (1.4%)
Speciﬁc contraindication to endoscopy 7 (1.4%)
Incomplete procedure due to agitated patient 5 (1%)
Unsuccessful esophageal intubation 2 (0.4%)
Total = 142.
Table 3 Endoscopic ﬁndings among cirrhotic patients with
acute UGI hemorrhage.
Endoscopic ﬁnding Incidence (%)
Varices 224 (62.6%)
Peptic ulcer 62 (17.3%)
Multiple lesions 19 (5.3%)
Portal hypertensive gastropathy 15 (4.2%)
Variceal treatment site ulcer 12 (3.4%)
No lesion found 10 (2.8%)
Mucosal erosions 7 (2%)
Esophagitis 4 (1.1%)
Vascular ectasias 3 (0.8%)
Gastric polyps 2 (0.6%)
Total = 358.
300 A. Gado et al.Table 4 Co-morbidities other than liver cirrhosis in patients
with acute variceal hemorrhage.
Co-morbidity Incidence (%)
Diabetes mellitus 95 (42.4%)
COPD*± respiratory failure 26 (11.6%)
Hypertension 16 (7.1%)
Ischemic heart disease 9 (4%)
Arrhythmia 5 (2.2%)
Prosthetic valve replacement 2 (0.9%)
Asthma 2 (0.9%)
Pneumonia 1 (0.4%)
Tuberculosis (under treatment) 1 (0.4%)
* Chronic obstructive pulmonary disease.hemodynamic data, initial hemoglobin level, resuscitative
efforts (blood transfusion requirement), Child status and
Rockall score. The endoscopic components of the database
included identiﬁcation of the time to endoscopy, bleeding
lesion and endoscopic therapy. Outcome measures were
rebleeding within ﬁve days of endoscopy, complications (organ
failure), the need for intervention (re-endoscopy, endoscopic
therapy) and mortality. The cause of death and the time inter-
val (in hours) between endoscopy and death was determined.
In patients with multiple admissions for acute VH, each
admission was treated separately. In case of death in the
second or subsequent admission, the patient’s data were
analyzed as ‘survivor’ in the initial admission(s) and as
‘deceased’ in the last admission.
The relationship between various clinical parameters at
admission to mortality was assessed. The parameters were:
gender, age, patient condition at the time of bleeding, presence
of ascites, hepatocellular carcinoma, other comorbidity, Child
class, presenting symptom, hemodynamic status, hemoglobin
level, transfusion need, time to endoscopy, blood in UGI tract
at the index endoscopy, source of bleeding, endoscopic ther-
apy, Rockall risk score, rebleeding within ﬁve days of endos-
copy and in-hospital complications. Univariate and
multivariate analyses were performed on the data. Eighteen
variables were studied and included in a multivariate analysis
using a logistic regression model.2.1. Statistical analysis
The data were registered, tabulated and analyzed statistically
using a program of SPSS version 15. Data on quantitative
variables are presented as mean and (SD), and numbers and
percentages are reported for qualitative variables. Differences
between the proportion of survivors and deceased were
assessed by using chi-squared. Variables with a P value of
<0.05 on univariate analysis were included in step-wise
multiple logistic regression analysis to identify independent
risk factors for mortality. Wald statistics was used to assess
the importance of each variable in the model, with P values
<0.05 taken as signiﬁcant.
3. Results
A total of 224 patients were analyzed. Sixty-three percent were
male and 37% female. Ages ranged from 20 to 87 years, mean
53 ± 10 years. One hundred and sixty-three patients (73%)
aged <60 years. Sixty-ﬁve patients (29%) had a history of
smoking. Seventy-one patients (32%) were taking aspirin or
non-steroidal anti-inﬂammatory drugs and two (1%) anticoag-
ulants. Three patients (1%) were consuming alcohol. Two
hundred and twelve patients (95%) were emergency admis-
sions and 12 (5%) were inpatients at the time of bleeding. Cir-
rhosis was newly diagnosed during hospitalization for VH in
22 patients (10%) and had been previously diagnosed in 202
(90%). The presenting symptoms were hematemesis in 139
patients (62%), melena in 27 (12%) and both in 58 (26%).
One hundred and eighty-ﬁve patients (83%) were hemodynam-
ically stable at admission and 39 (17%) were hemodynamically
unstable. Ninety patients (40%) had cirrhosis alone and 134
(60%) had cirrhosis and ascites. Thirty-three patients (15%)
had concomitant hepatocellular carcinoma. Forty-nine
patients (22%) were Child class A, 78 (35%) class B and 97
(43%) class C. Co-morbidities other than liver cirrhosis are
shown in Table 4. The mean hemoglobin concentration was
8 ± 2 g/dl and 44% had initial hemoglobin less than 7 g/dl.
One hundred and ﬁfty-four patients (69%) required blood
transfusion and the average number of transfused blood units
was three.
All patients underwent emergency endoscopy during admis-
sion. The mean time from presentation to endoscopy was
23 ± 22 h (30 min–168 h). Endoscopy was conducted within
24 h of presentation in 170 patients (76%). Endoscopy was
delayed more than 24 h in 54 patients (24%). The most
Table 5 Factors related to mortality among patients with acute VH.
Factors Deceased
(n= 19)
n (%)
Survival
(n= 205)
n (%)
P value
Gender
Male 13 (9%) 129 (91%) 0.635
Female 6 (7%) 76 (93%)
Age
<60 years 14 (9%) 149 (91%) 0.924
P60 years 5 (8%) 56 (92%)
Patient condition at the time of hemorrhage
Inpatients 2 (17%) 10 (83%) 0.296
Emergency admissions 17 (8%) 195 (92%)
Ascites
Liver cirrhosis alone 4 (4%) 86 (96%) 0.076
Liver cirrhosis and ascites 15 (11%) 119 (89%)
Hepatocellular carcinoma
Liver cirrhosis alone 14 (7%) 176 (93%) 0.157
Liver cirrhosis and hepatocellular carcinoma 5 (15%) 29 (85%)
Child class
Class A 1 (2%) 48 (98%) 0.004
Class B 3 (4%) 75 (96%)
Class C 15 (15%) 82 (85%)
Other comorbidity
Liver cirrhosis alone 5 (6%) 83 (94%) 0.226
Liver cirrhosis and other comorbidity 14 (10%) 122 (90%)
Presenting symptoms
Hematemesis 14 (10%) 125 (90%) 0.488
Melena 1 (4%) 26 (96%)
Hematemesis and melena 4 (7%) 54 (93%)
Hemodynamic status
Stable 11 (6%) 174 (94%) 0.003
Unstable 8 (21%) 31 (79%)
Hemoglobin levels
<7 gm/dl 7 (7%) 91 (93%) 0.526
P7 gm/dl 12 (10%) 114 (90%)
Transfusion needed
Transfusion needed 15 (10%) 139 (90%) 0.316
No blood transfusion 4 (6%) 66 (94%)
Time to endoscopy
Within 24 h 16 (9%) 154 (91%) 0.376
More than 24 h 3 (6%) 51 (94%)
Blood in UGI tract at the index endoscopy
Blood in UGI tract 17 (13%) 115 (87%) 0.005
No blood in UGI tract 2 (2%) 90 (98%)
Source of bleeding
Esophageal varices 13 (7%) 164 (93%) 0.236
Gastric varices 6 (13%) 41 (87%)
Endoscopic therapy applied
Injection sclerotherapy 15 (12%) 108 (88%) 0.006
0.001Band ligation 2 (2%) 92 (98%)
Both 2 (29%) 5 (71%)
Rockall risk score
Score 3–5 5 (4%) 118 (96%) 0.009
Score 6–8 14 (14%) 87 (86%)
(continued on next page)
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Table 5 (continued)
Factors Deceased
(n= 19)
n (%)
Survival
(n= 205)
n (%)
P value
Rebleeding within 5 days of endoscopy
Rebleeding 11 (48%) 12 (52%) 0.000
No rebleeding 8 (4%) 193 (96%)
In-hospital complications
Complications 8 (32%) 17 (68%) 0.000
No complications 11 (6%) 188 (94%)
Total = 224.
Table 6 Signiﬁcant predictor variables for mortality.
Signiﬁcant factors OR* 95% CI** AOR 95% CI P value
Hemodynamic status
Stable 4.1 10.9 + 1.5 5.5 22.3 + 1.4 0.017
Unstable
Child class
Class A 5.6 17.5 + 1.8 5.9 24 + 1.5 0.013
Class B
Class C
Blood in UGI tract
Blood in UGI tract 0.15 0.7–0.03 12.8 126.5 + 1.3 0.03
No blood in UGI tract
Rockall risk score
Score 3–5 3.8 10.9–1.3 1.4 6.9 + 0.2 0.7
Score 6–8
Endoscopic therapy
Injection sclerotherapy 6.4 28.7 + 1.4 0.15 2.5 + 0.01 0.155
Band ligation
Both
Rebleeding within 5 days
Rebleeding 0.45 0.1–0.01 25.4 109.2 + 5.9 0.000
No rebleeding
In-hospital complications
Complications 0.12 0.3–0.04 23.4 122.5 + 4.5 0.000
No complications
Total = 224.
* OR= odds ratio.
** CI = conﬁdence interval.
 AOR= adjusted odds ratio.
302 A. Gado et al.common reasons for delay were unavailable staff or equipment
in 28 patients, admission during weekends or holidays in 17,
hemodynamic instability in ﬁve and medical condition
(chronic obstructive pulmonary disease with respiratory dis-
tress and asthma) in four. One hundred and seventy-seven
patients (79%) bled from esophageal varices and 47 (21%)
from gastric varices. Blood in UGI tract was detected at the
index endoscopy in 132 patients (59%). The mean full Rockall
score was ﬁve and 101 patients (45%) had Rockall score six to
eight.
All patients received endoscopic therapy at the time of ini-
tial endoscopy. Injection sclerotherapy was performed in 123
patients (55%), band ligation in 94 (42%) and both in seven
(3%). Injection sclerotherapy with ethanolamine oleatesolution was used to treat 82 patients (37%), tissue adhesive
(histoacryl) in 32 (14%) and both in 16 (7%). Initial hemosta-
sis was achieved in 201 patients (90%) and 23 (10%) had reb-
leeding during the same admission. Seventeen patients (8%)
had therapy at a subsequent endoscopy for further bleeding.
Complications were reported in 25 patients (11%) during the
same hospitalization. The most frequent complications were
encephalopathy (5%), ascites (5%) and acute myocardial
infarction (1%). Two hundred and ﬁve patients (92%) were
discharged improved and 19 (8%) died within the ﬁrst two
weeks of their hospital admission. The time interval from
endoscopy to death ranged from 15 min to 288 h, mean
42 ± 70 h. Death was caused by continuing bleeding in 11
patients (5%), associated complications (mainly organ failure)
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and endoscopy was considered a possible cause (sedation
related complications in patients with major co-morbidity) in
two (1%). Univariate and multivariate analyses of variables
in relation to mortality are shown in Tables 5 and 6.4. Discussion
VH is a major complication of cirrhosis and portal hyperten-
sion, and is responsible for considerable morbidity and
mortality. In recent years, improvements in patient manage-
ment, including the use of terlipressin, prophylactic antibiotics,
variceal band ligation and trans-jugular intrahepatic porto-
systemic shunts, have resulted in a decline in in-hospital
mortality.13–17 Though the mortality rate has decreased with
advances in the management of VH, it continues to be
unacceptably high.17 Mortality in acute VH has decreased to
current levels by only approximately 20%.18
One of the most challenging topics for physicians in their
approach to the management of cirrhosis is the evaluation of
their patients’ prognosis. Those with cirrhosis who have VH
are at a substantially higher risk of mortality so the identiﬁca-
tion of factors that inﬂuence prognosis should be helpful in
planning their management. The factors that predict prognosis
however vary between studies.17 One of the difﬁculties with
predicting prognosis is that outcome is inﬂuenced not only
by the severity of the bleeding episode itself, but also by the
severity of the underlying liver disease.18 Currently, there is
no well-established model for the accurate prediction of sur-
vival in patients with cirrhosis following an episode of acute
VH.18 The aim of this study was to determine the predictors
of mortality in patients admitted to our hospital with acute
UGI hemorrhage who underwent endoscopy and conﬁrmed
to have VH.
Our in-hospital mortality rate of 8% is consistent with the
experience of other centers. Studies reported that in-hospital
mortality in cirrhotic patients admitted with acute VH ranged
from 7.4% to 14.2%.17,19,20 However, in other studies, the rate
of mortality was at least 20% at 6 week in patients with acute
VH.3,21 During the study period, 9% of cirrhotic patients
admitted to our hospital with acute UGI hemorrhage died rap-
idly after admission without having undergone an endoscopy
due to continued bleeding or rebleeding. Endoscopy was per-
formed on the morning of the second day and not on admis-
sion, so patients who died before performing the endoscopy
were not included in the analysis. The mean time from admis-
sion to death was six hours (range 25 min–18 h). The future
plan is to perform endoscopy as soon as the patients have been
resuscitated.
Univariate and multivariate analyses of variables in rela-
tion to mortality were performed. Eighteen variables were
studied and included in the analysis. Five variables were inde-
pendent predictors of death: the hemodynamic instability at
admission, Child class C, blood in UGI tract at the index
endoscopy, rebleeding within ﬁve days of endoscopy, and in-
hospital complications. Rebleeding within ﬁve days of endos-
copy and in-hospital complications were the most signiﬁcant.
Mortality was related to the severity of bleeding episode as
expressed by hemodynamic instability at admission and pres-
ence of blood in UGI tract at the index endoscopy. Our results
are in line with previously published data.17,22,23 Energeticresuscitation and early endoscopy might improve the progno-
sis of these patients.
Mortality was related to the severity of liver dysfunction as
expressed by Child classiﬁcation. The effectiveness of Child
classiﬁcation as a predictor of in-hospital death in cirrhotic
patients with acute VH proved to be similar to that reported
in other studies.22–25 The different statuses of liver cirrhosis
had different prognosis in terms of progression toward death.
This might help inform patients of the risks of potential
outcomes.
Mortality was related to the occurrence of rebleeding within
ﬁve days of endoscopy and in-hospital complication. Our
results are in line with previously published data.17,22,24 In hos-
pital rebleeding and complications played a highly signiﬁcant
role for stratiﬁcation of patients with high mortality. Both
occurred after admission which indicates that prognosis may
change from day to day. This necessitates intensive monitoring
of cirrhotic patients with acute VH during hospitalization and
further improvement to control bleeding might still improve
the prognosis of these patients.
Mortality was high in patients with a high risk Rockall
score. Surprisingly, patients with a high Rockall score had a
higher risk of mortality in univariate analysis while the risk
of mortality was not signiﬁcant in multivariate analysis. A high
Rockall score was not an independent risk of mortality in our
patients. The Rockall risk assessment score was devised to
allow prediction of the risk of rebleeding and death in patients
with UGI hemorrhage.26 Only 4.4% of patients included in the
initial study had esophageal varices, and analysis was not per-
formed according to the etiology of bleeding.27 The objective
of the Rockall score was to predict patient poor clinical out-
comes. It was also validated in many other settings, but with
diverse conclusions.26 Some authors reported good prediction
for re-bleeding, but poor prediction for death while the others
reported the opposite directions.26
Endoscopic therapy applied was effective in controlling VH
in 90% of patients. It was reported that endoscopic therapy
was effective in controlling VH in 84% and 90% of patients
in two studies.18,25 Mortality was high when endoscopic
therapy applied was injection sclerotherapy. Injection sclero-
therapy was commonly performed in patients with severe hem-
orrhage. Hemodynamic instability at admission and blood in
UGI tract at the index endoscopy were signiﬁcantly associated
with the injection sclerotherapy. The risk of mortality with
injection sclerotherapy was signiﬁcant in univariate analysis
and not signiﬁcant in multivariate analysis. Endoscopic ther-
apy applied was not an independent risk of mortality.
Eleven variables were not predictive of mortality: gender,
age > 60 years, inpatients at the time of bleeding, presence
of ascites, concomitant hepatocellular carcinoma, other
comorbidity, presentation with hematemesis, initial hemoglo-
bin less than 7 g/dl, transfusion need, delay to endoscopy more
than 24 h and source of bleeding. Most of these risk factors
were identiﬁed as predictors of mortality from acute VH in
published studies.5,6,21
The clinically and statistically important factors detected
from this study allow for early identiﬁcation of patients with
acute VH who are at a substantially increased risk of death
over the short term in Egypt. These patients may require care
in more specialized units during the bleeding episode, intensive
monitoring, energetic resuscitation, early endoscopy, various
options to control bleeding and aggressive follow-up in the
304 A. Gado et al.immediate post-variceal bleed setting. Our hospital, like most
governmental hospitals in Egypt, has limited resources so
our ﬁndings can be generalized to the broader community.
Limitations of this study: etiology of the underlying liver
disease, laboratory parameters and variceal size were not
assessed. Additionally, the initial version of Child classiﬁcation,
which includes a subjective criterion (nutritional status), was
used. Some patients whose individual values fall into different
groups could not be properly categorized in this version. The
study was not designed to collect the parameters necessary
for the accurate calculation of the Child–Pugh score.
5. Conclusion
This study demonstrates that the hemodynamic instability at
admission, Child class C, blood in UGI tract at the index
endoscopy, rebleeding within ﬁve days of endoscopy and in-
hospital complications were independent predictors of mortal-
ity after the acute VH episode with rebleeding within ﬁve days
of endoscopy and in-hospital complications being the most sig-
niﬁcant. This study may guide clinicians to pay particular
attention to patients with these risks. For future implications,
these risk characteristics may be used in the process of VH risk
stratiﬁcation.
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